Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Probiotics on Lipidomic Profile and Disease Evolution in ALS-FTDSD Patients: A Randomized Multicenter, Double-blind, Phase II, Placebo-controlled, Parallel Trial.

NCT06051123 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT06051123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06051123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Probiotics on Lipidomic Profile and Disease Evolution in ALS-FTDSD Patients: A Randomized Multicenter, Double-blind, Phase II, Placebo-controlled, Parallel Trial.
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Not applicable
Overall status
Recruiting
Start date
January 1, 2024
Completion date
February 28, 2027
Enrollment
150 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

als (amyotrophic lateral sclerosis), alsftd, frontal temporal dementia (ftd)